These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 772555)

  • 41. The response to factor VIII infusion in inhibitor patients.
    Allain JP; Verroust F
    Prog Clin Biol Res; 1984; 150():99-108. PubMed ID: 6431445
    [No Abstract]   [Full Text] [Related]  

  • 42. [Macrohaematuria post-partum: an unusual case of acquired haemophilia after pregnancy].
    Prencipe MA; D'Errico M; Di Giorgio G; Gatta G; Gesuete A; Nobile M; Stallone C
    G Ital Nefrol; 2002; 19(2):204-8. PubMed ID: 12195420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical heterogeneity of acquired hemophilia A: a description of 4 cases.
    Franchini M; Girelli D; Olivieri O; Bozzini C; Guiotto M; Zardini G; Lippi G; Manzato F; Gandin G
    Haematologica; 2005 Mar; 90(3):ECR16. PubMed ID: 15753057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acquired hemophilia.
    Bouvry P; Recloux P
    Haematologica; 1994; 79(6):550-6. PubMed ID: 7896216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors.
    Sakurai Y; Shima M; Tanaka I; Fukuda K; Yoshida K; Yoshioka A
    Haematologica; 2004 Jun; 89(6):696-703. PubMed ID: 15194537
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factor VIII inhibitors, natural history and management.
    Allain JP
    Southeast Asian J Trop Med Public Health; 1979 Jun; 10(2):241-2. PubMed ID: 524148
    [No Abstract]   [Full Text] [Related]  

  • 49. Durable responses to rituximab in acquired factor VIII deficiency.
    Singh AG; Hamarneh IS; Karwal MW; Lentz SR
    Thromb Haemost; 2011 Jul; 106(1):172-4. PubMed ID: 21544323
    [No Abstract]   [Full Text] [Related]  

  • 50. Absence of anamnestic response after transfusion of washed red blood cells in haemophilia A patients with antibody to factor VIII.
    Laurian Y; Girma JP; Allain JP; Verroust F; Larrieu MJ
    Scand J Haematol; 1982 Mar; 28(3):233-7. PubMed ID: 6806896
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idiopathic inhibitor of factor VIII and its treatment by immunosuppression.
    Ting HC; Wang F; Por P; Nurulhuda A
    Acta Haematol; 1980; 64(4):236-8. PubMed ID: 6781207
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618-->Ser mutation responsive to immune tolerance induction and cyclophosphamide.
    Vlot AJ; Wittebol S; Strengers PF; Turenhout EA; Voorberg J; van den Berg HM; Mauser-Bunschoten EP
    Br J Haematol; 2002 Apr; 117(1):136-40. PubMed ID: 11918545
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunosuppressive therapy of Factor VIII inhibitors.
    Hultin MB; Shapiro SS; Bowman HS; Gill FM; Andrews AT; Martinez J; Eyster EM; Sherwood WC
    Blood; 1976 Jul; 48(1):95-108. PubMed ID: 947408
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful immunoadsorption of life-threatening bleeding in factor VIII inhibitor disease, but no long-term remission with anti-CD20 treatment.
    Grahammer F; Fischer KG
    BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26323976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Factor VIII inhibitors--their characteristics and clinical significance].
    Dmoszyńska A; Kniaź M; Sokołowska B
    Pol Arch Med Wewn; 1987 Dec; 78(6):333-40. PubMed ID: 3152083
    [No Abstract]   [Full Text] [Related]  

  • 56. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A.
    Allain JP; Frommel D
    Blood; 1976 Jun; 47(6):973-82. PubMed ID: 1276479
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hemophilia: acquired modifications of the genetic disorder.
    Hampton JW; Warner D
    Ann N Y Acad Sci; 1975 Jan; 240():405-6. PubMed ID: 1053884
    [No Abstract]   [Full Text] [Related]  

  • 58. Haemophilia.
    Gétaz EP; Staples WG; Lurie A
    S Afr Med J; 1977 Oct; 52(15):595-601. PubMed ID: 303383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug-induced anti-factor VIII antibodies: a systematic review.
    Franchini M; Capra F; Nicolini N; Veneri D; Manzato F; Baudo F; Lippi G
    Med Sci Monit; 2007 Apr; 13(4):RA55-61. PubMed ID: 17392659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose.
    Van Leeuwen EF; Mauser-Bunschoten EP; Van Dijken PJ; Kok AJ; Sjamsoedin-Visser EJ; Sixma JJ
    Br J Haematol; 1986 Oct; 64(2):291-7. PubMed ID: 3096366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.